Who We Are
BeiGene is a global biotechnology company developing innovative and affordable cancer medicines for more patients around the world.
We are a leading oncology R&D innovator with a deep, diverse pipeline fueled by one of the industry’s largest and most productive research teams of its kind. Our two cornerstone medicines, BTK inhibitor BRUKINSA® (zanubrutinib) and PD-1 inhibitor TEVIMBRA® (tislelizumab), demonstrate the strength of our science and our mission to improve treatment outcomes for patients.
Today, our more than 10,000 colleagues operate in more than 30 markets across five continents. More than 800,000 patients have been treated with our medicines, reflecting our expansive global reach and deep commitment to access.
Our Story
Founded in 2010 by Chairman and CEO John V. Oyler and world-renowned scientist Xiaodong Wang, BeiGene was built on the belief that access to innovative cancer care is a global imperative and requires a truly global vision to achieve.
We have built a globally inclusive, predominantly in-house clinical development model designed to lower the time and cost of development with the goal of greater affordability and accessibility for patients around the world. We have enrolled more than 20,000 patients in our clinical trials to date, and continue to advance and expand our pipeline to reach even more.
Our fully integrated manufacturing capabilities also allow us to greatly speed our clinical development efforts while ensuring the highest-quality production of our clinical and commercial portfolio of small-molecule, biologics and emerging modality therapeutics. Our manufacturing facility and clinical R&D center of excellence at the Princeton West Innovation Campus will provide state-of-the-art, clinical- and commercial-stage U.S. biologic pharmaceutical manufacturing, late-stage research and clinical development capabilities that complement the company’s strengths in these and other areas.
Every day we strive to create high-quality, innovative medicines faster and more affordably for patients. Meanwhile, we have built a global team that operates under the highest standards of sustainability, with a resolute commitment to access and Diversity, Equity, Inclusion and Belonging (DEI&B) initiatives.